profit from every $100 of sales.
$0$100
Cardiol Therapeutics
$1.00-3.85% today
-2.0% in 1 year
1-year low $0.931-year high $2.29
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Cardiol Therapeutics sold, what it kept, and what it did with the cash.
Sales went from CA$0 in 2022 to CA$0 in 2025, with -CA$33.8 million of profit last year.
SalesProfit
Cardiol Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cardiol Therapeutics | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Cardiol Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -41 | -30 | -40 | -34 | |
| -41 | -30 | -40 | -34 | |
| -31 | -28 | -37 | -34 | |
| -0.49 | -0.44 | -0.51 | -0.39 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 62 | 37 | 32 | 24 |
| Cash | 59 | 35 | 31 | 21 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 10 | 8 | 7 | 6 |
| 52 | 28 | 25 | 18 | |
| 63 | 64 | 72 | 87 | |
| -62.5% | -82.8% | -127.9% | -150.6% | |
| -59.3% | -99.6% | -148.3% | -189.2% |
Cash flow
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -27 | -25 | -25 | -24 | |
| 0 | 0 | 0 | 0 | |
| -27 | -25 | -25 | -24 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 5 | 4 | 14 | 11 |
Valuation
- –
- –
- –
- 10.1×
- –
- –
- –
- -13.1%
- -18.6%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -190.6%
- -100.4%
- -238.0%
- -143.2%
- -191.0%
- –
Growth
- –
- –
- +4.8%
- –
- +19.1%
Financial health
- 0.6×
- 0.01
- 0.5%
- –
- 4.16
- 4.16
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 871
Bottom 9%of 986
What analysts expect
- Average price target
- $8.00
- Range
- $8.00 – $8.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.07 | -0.07 | +0.0% |
| Mar 30, 2026 | -0.05 | -0.09 | +43.4% |
| Nov 13, 2025 | -0.09 | -0.09 | +0.0% |
| Aug 14, 2025 | -0.07 | -0.11 | +36.4% |
| May 13, 2025 | -0.10 | -0.13 | +23.1% |
| Mar 31, 2025 | -0.07 | -0.08 | +12.5% |
| Nov 14, 2024 | -0.13 | -0.10 | −30.0% |
| Aug 12, 2024 | -0.07 | -0.10 | +30.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
24No pass
Benjamin Graham
40No pass
Philip Fisher
31No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
24No pass
Terry Smith
21No pass
Questions about Cardiol Therapeutics
Is Cardiol Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cardiol Therapeutics AI analysis
What does Cardiol Therapeutics do?
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). It is in Drug Manufacturers - Specialty & Generic.
Does Cardiol Therapeutics pay a dividend?
No. Cardiol Therapeutics does not pay a dividend at the moment.
Is Cardiol Therapeutics stock halal?
Yes. Cardiol Therapeutics passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has Cardiol Therapeutics stock done over the past year?
Down 2.0% over the past twelve months, to $1.00. It traded between $0.93 and $2.29 and is 56.2% below its high.
Who are Cardiol Therapeutics's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Cardiol Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.